Press Releases
home
german
disclaimer
sitemap
search
ok
print
links
imprint
Company
Company Profil
Business Strategy
Management
Contact
Imprint
Products & Pipeline
Products and clinical projects
Targeted Indication
News
News
Press Releases
Ad hoc Press Releases
Conferences and Events
Investor Relations
Investor Relations Contact
The MediGene Stock
Financial Calendar
Conference Calendar
Reports
General Meeting
News
Analysts Coverage
Corporate Governance
Company Presentation
Career Opportunities
Career Opportunities
Partnering & Licensing
Partnering & Licensing
Press Releases 2010
Press Releases 2009
Press Releases 2008
Press Releases 2007
Press Releases 2006
Press Releases 2005
Press Releases 2004
Press Releases 2003
Press Releases
If you wish to be informed regularly about MediGene's press releases, you can
subscribe
to our investor's newsletter.
MediGene sells full European rights for Eligard® to Astellas for EUR 25 million and ongoing royalties
2010-07-19
MediGene reports additional phase II results of EndoTAG(TM)-1 for the treatment of triple receptor-negative breast cancer
2010-06-24
MediGene continues the global licensure of Veregen® through agreements with GC Rise in China and JS Bio Pharm in South Korea
2010-05-10
MediGene AG reports on first quarter of 2010: total revenue increased – cost constant
2010-05-07
MediGene publishes first, preliminary results obtained in a phase II clinical trial of EndoTAG(TM)-1 for the treatment of triple receptor-negative breast cancer
2010-05-06
New CFO Arnd Christ to take up position at MediGene in April
2010-04-19
MediGene AG divests Oncolytic Herpes Simplex Viruses (oHSV) program to Catherex, Inc.
2010-04-13
MediGene Signs Agreement with Meditrina for the Commercialization of Veregen® in Greece and Cyprus
2010-04-01
MediGene appoints Arnd Christ as Chief Financial Officer as Successor to Dr. Thomas Klaue
2010-03-26
MediGene AG Reports Financial Results for the 2009 Fiscal Year
2010-03-26
MediGene’s Veregen® launched by Solvay in Germany
2010-03-01
MediGene and Teva sign agreement to commercialize Veregen™ in Israel
2010-02-22
Für weitere Informationen wenden Sie sich bitte an Dr. Georg Dönges oder Julia Hofmann,
Public Relations
, MediGene AG
Kontakt